Neuraxpharm Group has announced that the National Institute for Health and Care Excellence (NICE) has recommended ublituximab (BRIUMVI®) for the treatment of relapsing-remitting multiple sclerosis (RRMS).
This approval marks a significant milestone for the European specialty pharmaceutical company.
“Today’s milestone reflects our commitment to improving the lives of people living with MS in the UK,” said Mark Slater, UK General Manager of Neuraxpharm…
